Barclays raised the firm’s price target on Teva Pharmaceutical Industries to $17 from $15 and keeps an Overweight rating on the shares after meeting with management. The analyst says the company has confidence in meeting both its 2024 guidance 2027 goal. The firm increased estimates citing the “strong” 2024 guide and “growth engines aligning” across the generic and specialty units.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TEVA: